Translating an innovation from the research stage into early-stage development for commercialization can be facilitated by using targeted consulting agencies. Join us as we learn about common practices for evaluating and hiring consulting agencies for your innovation. Please visit the session summary to learn more about this seminar and our speakers.
Get to know your NOVA BioHub! This new series provides a mechanism for our life science community to network, share ideas, and get to know one another. Lunch will be provided for those who would like to join us in-person. There will also be an opportunity to join virtually. Speakers:Cohava Gelber, PhD, MBA, CEO, Serpin PharmaBo …
Building a successful company requires expanding expertise beyond scientific research. In this seminar, attendees will learn about key factors in creating and managing a business development team versus a research-focused team. Please visit the session summary to learn more about this seminar and the speakers.
Join Johnson & Johnson Innovation on December 7th to hear their panel of experts, including Whurley, Founder & CEO, Strangeworks, Denise Ruffner Chief Business Officer, Atom Computing, & Sanjoy Ray, PhD Senior Director, Oncology & Immunology TA R&D IT, Janssen Pharmaceuticals , discuss their views on the application of quantum computing to drug discovery, its …
What should the Virginia life science industry expect as a result of the November elections? What opportunities exist for our companies under the Build Back Better Act? How will potential federal and state laws and policies help (or hurt) the industry? Please join our December Luncheon as expert panelists shed light on important policy updates …
CvilleBioHub organizes a panel discussion on how longstanding changes and innovations driven by the COVID era will impact the future environment for clinical trials and research. Innovations in the clinical trial space caused by the COVID era are here to stay. In this panel, we discuss where innovation and disruption are happening, how companies are …
An NIH Technology Opportunity Webinar Join the NIH on November 17 for a technology webinar. Attendees will hear from NICHD’s Dr. Tracey Rouault about the potential to formulate the compound, Tempol, into a preventative and oral treatment for COVID-19. The replication of the SARS-CoV-2’s genome is prompted by the presence of RNA-dependent RNA Polymerase …
NOW ALL VIRTUAL Biotech Showcase™ is an investor and networking conference devoted to providing private and micro-mid-cap biotechnology companies an opportunity to present to and meet with investors and biopharmaceutical executives. We are committed to serving the life sciences industry during these challenging times by providing two options to attend. We understand travel restrictions and …
Visualizing the Benefits of 3D Cell Culture Broadcast Date: November 5, 2021 Time: 8:00 am PT, 11:00 am ET, 17:00 CET Drug discovery screening is a complex endeavor that can often yield promising results toward new therapies. When combined with advanced 3D cell culture techniques like spheroids, the screening process becomes more physiologically relevant, but the …
How to Valuate your Biotechnology Company Do you understand the value of your biotechnology company? Virginia Bio makes sure you do. Join us for our next luncheon on Thursday, November 18th, and hear it from Cherry Bekaert’s Anna Townsand. Anna is a Partner of the Valuation services and has extensive business valuation and financial modeling experience.
What is HealthHacks? HealthHacks is a 24-hour sprint of intense innovation and problem solving focused on unmet medical needs. Participants address challenges through teamwork, solution ideation, programming, rapid prototyping, developing flow processes and more. While one of only a few medical hackathons in the U.S., HealthHacks is rare by focusing predominantly on medical device product …
Wednesday, November 10, 2021 Shift Retail Lab at VCU 1235 West Broad Street, Richmond, VA The inaugural Pitch Virginia event, powered by Activation Capital, will take place on Wednesday, November 10 at the newly opened Shift Retail Lab at VCU, an initiative of the VCU da Vinci Center. Kicking off with a design thinking workshop …
Bench to Community – Translating New Ideas Into Clinical Practice Session 2: Small Business Innovation Research Funding for Startups When: Thursday, October 14, 2021 | 4 p.m. – 5:30 p.m. Featured Speakers: Robert Brooke, Director of Federal Fund Programs, CIT Jason Reed, Professor, VCU Department of Physics Description: In …
The Peer Review process at the National Institutes of Health is unique — fully understanding this process can improve your chances of success in SBIR, STTR and other peer reviewed grant submissions to NIH. This session discusses the peer review process at NIH and tips on how to craft your proposal with the reviewers in mind. Presented …
Your Specific Aims page is a critically important component of your SBIR/STTR application and typically the first page reviewers read. Yet, this one page is often the most difficult section to write! You need to “hook” the reviewers from the start as well as provide key information about your technology, the innovation and your team. …
The National Institutes of Health award over $1B annually to small businesses. This workshop is a must if you are considering a National Institutes of Health (NIH) SBIR or STTR submission. In addition to up-to-date information on the SBIR/STTR programs, you’ll receive detailed instruction on developing a competitive proposal for NIH’s SBIR/STTR program. Session Topics …
This live, interactive session provides viewers an overview of the National Science Foundation’s (NSF) SBIR/STTR grant programs and provides a section by section description on writing an NSF SBIR/STTR proposal. With an NSF SBIR or STTR, YOU write the topic that you want funding for! Ideal for anyone considering an NSF SBIR/STTR submission in the …
October is Breast Cancer Awareness Month. Join us in learning more about companies working to improve the lives of cancer patients in the Commonwealth and beyond. Speakers: Samy Y. Lamouille, serves as the CEO of Acomhal Research, Inc. and Assistant Professor at Fralin Biomedical Research Institute at Virginia Tech Carilion. He is an experienced cell …
Are you an innovator working on a potential solution that may allow us to predict, detect, prevent, or treat emerging infectious diseases? Tune into Power Surge on October 25th to learn about opportunities available within BLUE KNIGHT™, as well as insight on areas of interest and the application process. The session will conclude with a …
The complexity and heterogeneity of chronic immune diseases has led to barriers in the development of novel therapies and treatments for patients. However, by looking to the global ecosystem, harnessing scientific advances in understanding disease pathophysiology and identifying and employing biomarkers for mechanistic stratification, there is hope. Join Johnson & Johnson Innovation on September …
Date: November 9, 2021 Time: 8:30 – 5:30 Location: MITRE Campus, McLean, VA 2nd Annual Mid-Atlantic Synthetic Biology Symposium Co-hosted by the SynBio at the University of Virginia and The MITRE Corporation, this meeting will bring together experts from industry, government, and academia. Join us to hear the latest research and of opportunities in SynBio …
Are you an innovator working on a potential solution that may allow us to predict, detect, prevent, or treat emerging infectious diseases? Are you developing science that may help protect vulnerable populations from future health threats? BLUE KNIGHT™, a joint initiative between Johnson & Johnson Innovation – JLABS (‘JLABS’) and the Biomedical Advanced Research and …
The current pandemic has brought to the forefront the need for new solutions that can bolster our preparedness and the need to invest in potential solutions today that could help us be better prepared for the known and unknown threats of tomorrow. Venture funds and angel investors are seeking to do this by investing in a wide range of opportunities that focus on …
Antimicrobial resistance (AMR) is a growing public health concern and a threat to global health security. 700,000 people die each year from AMR infections, and it is estimated that by 2050, AMR infections could cause 10 million deaths per year1. Multi-drug resistant (MDR) bacteria are a particular threat as existing antibiotics are becoming ineffective. During …